Patents Examined by Lila Feisee
  • Patent number: 6013479
    Abstract: The invention provides a human Emr1-like G protein coupled receptor (EGPCR) and polynucleotides which identify and encode EGPCR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EGPCR.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: January 11, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Hong Xu, Victoria L. Cohan, Susan G. Stuart
  • Patent number: 6010999
    Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing said derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 4, 2000
    Assignee: American Cyanamid Company
    Inventors: Michael Joseph Daley, Brian Lee Buckwalter, Susan Mancini Cady, Hong-Ming Shieh, Peter Bohlen, Andrew P. Seddon
  • Patent number: 6004554
    Abstract: The present invention relates generally to methods and compositions for targeting the vasulature of solid tumors using immunologcially-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: December 21, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Francis J. Burrows
  • Patent number: 6004555
    Abstract: Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 21, 1999
    Assignees: Board of Regents, The University of Texas System, The Scripps Research Institute
    Inventors: Philip E. Thorpe, Thomas S. Edgington
  • Patent number: 5998170
    Abstract: Nucleic acid molecules are described which are useful in vectors, transformed or transfected host cells, and methods for the recombinant expression of hepatocyte growth-specific polypeptide members of the FGF family.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: December 7, 1999
    Assignee: Amgen Inc.
    Inventors: Tsutomu Arakawa, Dimitry Michael Danilenko, Nobuyuki Itoh, Francis Hall Martin
  • Patent number: 5997865
    Abstract: Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: December 7, 1999
    Inventors: Brian D. Bennett, Susan D. Broz, William Matthews, Francis C. Zeigler
  • Patent number: 5989832
    Abstract: Methods are provided for screening for inhibitors of microbial efflux pumps including those which export antibiotics. The screening methods are based on the increase in the intracellular concentration of a compound, such as an antibiotic, when the bacterial cells are contacted with an efflux pump inhibitor. In addition, this invention provides pharmaceutical compositions containing such efflux pump inhibitors, and methods for treating microbial infections using those compositions.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: November 23, 1999
    Assignee: Microcide Pharmaceuticals, Inc.
    Inventors: Joaquim Trias, Suzanne Chamberland, Scott J. Hecker, Ving J. Lee
  • Patent number: 5989565
    Abstract: Methods are provided for eluting peptides that are bound to major histocompatibility complex ("MHC") molecules expressed on the cell surfaces of viable cells that have at least one MHC-peptide complex on the surfaces of the cells, the method comprising incubating the cells in the presence of peptide elution buffer, preferably comprising iso-osmotic, citrate-phosphate buffer at a pH of approximately 3.3, for between about 15 seconds and one minute. Using these methods a naturally processed melanoma peptide recognized by CD8.sup.+ cytotoxic T lymphocytes has been identified.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 23, 1999
    Assignee: University of Pittsburgh
    Inventors: Walter J. Storkus, Michael T. Lotze
  • Patent number: 5989861
    Abstract: The invention provides a human ion transport-like protein (HITLP) and polynucleotides which identify and encode HITLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HITLP.
    Type: Grant
    Filed: July 22, 1998
    Date of Patent: November 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Neil C. Corley, Karl J. Guegler, Chandra Patterson
  • Patent number: 5987390
    Abstract: Methods and computer systems for identifying protein classes from nucleic acid or amino acid sequence data are disclosed.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: November 16, 1999
    Assignee: Smithkline Beecham Corporation
    Inventor: Istvan Ladunga
  • Patent number: 5985583
    Abstract: The present invention relates to the GnRH-R genes and proteins. The DNA sequence disclosed herein may be engineered into expression systems designed for the production of GnRH-R and/or cell lines which express the GnRH-R and preferably respond to GnRH induced signal transduction. Such cell lines may advantageously be used for screening and identifying GnRH agonists and antagonists. In accordance with another aspect of the invention, the GnRH DNA, antisense oligonucleotide sequences, the GnRH expression products, and antibodies to such products may be used in the diagnosis and therapy of reproductive disorders associated with abnormal expression of the GnRH-R; e.g., overexpression, underexpression or expression of a dysfunctional mutant receptor. Transgenic animals containing the GnRH-R transgene may be used as animal models for the evaluation of GnRH analogs in vivo.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: November 16, 1999
    Assignee: Mount Sinai School of Medicine of The City University of New York
    Inventor: Stuart C. Sealfon
  • Patent number: 5985270
    Abstract: The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon-.alpha., interferon-.alpha., interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: November 16, 1999
    Assignee: Fordham University
    Inventor: Pramod K. Srivastava
  • Patent number: 5981220
    Abstract: A human epidermal differentiation factor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating and/or preventing skin diseases. Diagnostic assays for detecting mutations in a nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: November 9, 1999
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Ping Feng, Patrick J. Dillon, Reiner Gentz
  • Patent number: 5980896
    Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: November 9, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber, Clay Siegall, Stephen McAndrew
  • Patent number: 5981218
    Abstract: The present invention relates to four novel human genes amplified and overexpressed in breast carcinoma and located on the q11-q21.3 region of chromosome 17. The four novel genes are useful in breast cancer prognosis. The present invention also relates to a fifth novel human gene expressed in breast carcinoma and located on chromosome 6q22-q23. A sixth novel gene is also described that is the murine homolog of the human D52 gene. The genes and gene fragments of the present invention are themselves useful as DNA and RNA probes for gene mapping by in situ hybridization with chromosomes and for detecting gene expression in human tissues (including breast and lymph node tissues) by Northern blot analysis.
    Type: Grant
    Filed: July 31, 1996
    Date of Patent: November 9, 1999
    Assignees: Bristol-Myers Squibb Company, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur
    Inventors: Marie-Christine Rio, Catherine Tomasetto, Paul Basset, Jennifer Byrne
  • Patent number: 5981194
    Abstract: The invention related to a GPI-anchored p97 and a soluble form of p97 and derivatives thereof and methods for preparing the same. Methods of using p97 in modulating iron transport, in the delivery of therapeutic agents, and in the treatment of conditions involving disturbances in iron metabolism are described. The treatment and diagnosis of Alzheimer's Disease in view of the finding that p97 and transferrin receptor are markers for microglial cells associated with senile plaques are also described.
    Type: Grant
    Filed: August 31, 1995
    Date of Patent: November 9, 1999
    Assignee: University of British Columbia
    Inventors: Wilfred A. Jefferies, Patrick L. McGeer, Sylvia Rothenberger, Michael R. Food, Tatsuo Yamada, Malcolm Kennard
  • Patent number: 5981469
    Abstract: A 78 residue polypeptide comprising the following amino acid sequenceGYFCESCRKIIQKLEDMVGPQPNEDTVTQAASQVCDKLKILRGLCKKIMRSFLRRISWDILTGKK PQAICVDIKICKE [SEQ ID NO:1]:and functional derivatives and pharmaceutically acceptable salts thereof, said sequence comprising intra-linked half-cysteines; pharmaceutical composition containing such polypeptide as an active ingredient; a method for inhibiting microbial growth and cancer cell growth in animals including man; and nucleotide sequence corresponding to such polypeptide.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: November 9, 1999
    Inventors: Mats Andersson, Hans G Boman, Hans Jornvall, Viktor Mutt
  • Patent number: 5981222
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: November 9, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Vikki Spaulding
  • Patent number: 5981725
    Abstract: Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 9, 1999
    Assignees: The Johns Hopkins Univiersity, Duke University
    Inventors: Bert Vogelstein, Darell Bigner
  • Patent number: 5981200
    Abstract: This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: November 9, 1999
    Assignees: The Regents of the University of California, Aurora Biosciences Corporation
    Inventors: Roger Y. Tsien, Roger Heim, Andrew Cubitt